Skip to main content
SpringerLink
Log in

Microbiological Background

  • Chapter
  • First Online:
Infections in Hematology

  • 1547 Accesses

Abstract

Several bacteria and fungi can cause severe infections in hematology patients. During last three decades gram-positive bacteria including coagulase-negative staphylococci, viridans streptococci and enterococci have been the most frequent pathogens causing bacteremia in neutropenic patients. This picture has recently changed so that the incidence of infections with enteric gram-negatives and non-fermentative bacteria has dramatically increased and at least in some centers exceeded the rates of gram-positive bacterial infections. Particular problems included quinolone-resistant Escherichia coli, extended-spectrum beta-lactamase production in enteric bacteria and carbapenemase synthesis in E. coli, klebsiellae, Pseudomonas aeruginosa and Acinetobacter spp. Stenotrophomonas maltophilia is another important non-fermentative responsible for severe infections in this patient population. In most cases these bacteria posses various mechanisms causing multidrug resistance patterns. Prophylactic and empirical antibacterial regimens need to be adapted according to local epidemiology, particularly in those places where these resistant bacteria are prevalent both in-hospital or in the outpatient settings.

Among the fungal pathogens, Aspergillus spp. and Candida spp. are far more prevalent. Non-albicans Candida spp. are more frequently isolated than C. albicans in patients with acute leukemia or in those undergoing stem cell transplantation. Aspergillus spp. are the leading fungal pathogens in hematological cancer patients among which A. fumigatus is the most frequent one. Emerging triazoles resistance has been reported in A. fumigatus. Non-aspergillus mold infections have been on rise during the last two decades and this may be related with the use of antifungals with lesser or without any activity on these molds. While mortality due to A. fumigatus has been steadily decreasing in hematology patients, very high mortality rates are still being observed in those patients infected with non-aspergillus molds.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Adler A, Yaniv I, Solter E, et al. Catheter-associated bloodstream infections in pediatric hematology-oncology patients: factors associated with catheter removal and recurrence. J Pediatr Hematol Oncol. 2006;28:23–8.

    PubMed  Google Scholar 

  2. Aisenberg G, Rolston KV, Safdar A. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989–2003). Cancer. 2004;101:2134–40.

    PubMed  Google Scholar 

  3. Akan H, Akova M, Ataoglu H, et al. Rhodococcus equi and Nocardia brasiliensis infection of the brain and liver in a patient with acute nonlymphoblastic leukemia. Eur J Clin Microbiol Infect Dis. 1998;17:737–9.

    CAS  PubMed  Google Scholar 

  4. Akova M. Emerging problem pathogens: a review of resistance patterns over time. Int J Infect Dis. 2006;10:S3–8.

    CAS  Google Scholar 

  5. Akova M, Akalin HE, Uzun O, Gur D. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis. 1991;10:598–9.

    CAS  PubMed  Google Scholar 

  6. Akova M, Bonfiglio G, Livermore DM. Susceptibility to beta-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high- and low-level constitutive expression of L1 and L2 beta-lactamases. J Med Microbiol. 1991;35:208–13.

    CAS  PubMed  Google Scholar 

  7. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experiences with carbapenemase producing Gram-negative bacteria. Clin Microbiol Infect. 2012;18:439–48.

    CAS  PubMed  Google Scholar 

  8. Aksu G, Ruhi MZ, Akan H, et al. Aerobic bacterial and fungal infections in peripheral blood stem cell transplants. Bone Marrow Transplant. 2001;27:201–5.

    CAS  PubMed  Google Scholar 

  9. Al-Tonbary YA, Soliman OE, Sarhan MM, et al. Nosocomial infections and fever of unknown origin in pediatric hematology/oncology unit: a retrospective annual study. World J Pediatr. 2011;7:60–4.

    PubMed  Google Scholar 

  10. Alanio A, Sitterle E, Liance M, et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother. 2011;66:371–4.

    CAS  PubMed  Google Scholar 

  11. Almyroudis NG, Fuller A, Jakubowski A, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005;7:11–7.

    CAS  PubMed  Google Scholar 

  12. Almyroudis NG, Lesse AJ, Hahn T, et al. Molecular epidemiology and risk factors for colonization by vancomycin-resistant Enterococcus in patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2011;32:490–6.

    CAS  PubMed  Google Scholar 

  13. Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012;54:1053–63.

    PubMed Central  PubMed  Google Scholar 

  14. Alp S, Arikan-Akdagli S, Gulmez D, et al. Epidemiology of Candida bloodstream infections and antifungal susceptibility profiles: 10-year experience with 381 candidaemia episodes in a tertiary care university centre. 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Abst. No. 3233. European Society of Clinical Microbiology and Infectious Diseases (ESCMID), London.

    Google Scholar 

  15. Apisarnthanarak A, Fraser VJ, Dunne WM, et al. Stenotrophomonas maltophilia intestinal colonization in hospitalized oncology patients with diarrhea. Clin Infect Dis. 2003;37:1131–5.

    PubMed  Google Scholar 

  16. Apisarnthanarak A, Mayfield JL, Garison T, et al. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect Control Hosp Epidemiol. 2003;24:269–74.

    PubMed  Google Scholar 

  17. Araoka H, Baba M, Yoneyama A. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996–2009. Eur J Clin Microbiol Infect Dis. 2010;29:605–8.

    CAS  PubMed  Google Scholar 

  18. Arendrup MC, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect. 2014;20 Suppl 3:76–98.

    CAS  PubMed  Google Scholar 

  19. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol. 1999;37:3946–51.

    CAS  PubMed Central  PubMed  Google Scholar 

  20. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother. 2001;45:327–30.

    CAS  PubMed Central  PubMed  Google Scholar 

  21. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 2002;46:245–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  22. Ashour HM, el-Sharif A. Microbial spectrum and antibiotic susceptibility profile of Gram-positive aerobic bacteria isolated from cancer patients. J Clin Oncol. 2007;25:5763–9.

    PubMed  Google Scholar 

  23. Asturias EJ, Corral JE, Quezada J. Evaluation of six risk factors for the development of bacteremia in children with cancer and febrile neutropenia. Curr Oncol. 2010;17:59–63.

    CAS  PubMed Central  PubMed  Google Scholar 

  24. Bakhshi S, Padmanjali KS, Arya LS. Infections in childhood acute lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes. Pediatr Hematol Oncol. 2008;25:385–92.

    PubMed  Google Scholar 

  25. Baskaran ND, Gan GG, Adeeba K, Sam IC. Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia. Int J Infect Dis. 2007;11:513–7.

    PubMed  Google Scholar 

  26. Becker K, vonEiff C. Staphylococcus, micrococcus, and other catalase-positive cocci. In: Versalovic J, editor. Manual of Clinical Microbiology. 10th ed. Washington, DC: ASM Press; 2012. p. 308–30.

    Google Scholar 

  27. Beebe JL, Koneman EW. Recovery of uncommon bacteria from blood: association with neoplastic disease. Clin Microbiol Rev. 1995;8:336–56.

    CAS  PubMed Central  PubMed  Google Scholar 

  28. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia. 2006;162:1–15.

    PubMed  Google Scholar 

  29. Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV. Incidence of fluoroquinolone-resistant and extended-spectrum beta-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy. 2011;57:335–8.

    CAS  PubMed  Google Scholar 

  30. Biavasco F, Vignaroli C, Varaldo PE. Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis. 2000;19:403–17.

    CAS  PubMed  Google Scholar 

  31. Blahova J, Kralikova K, Krcmery Sr V, et al. Four years of monitoring antibiotic resistance in microorganisms from bacteremic patients. J Chemother. 2007;19:665–9.

    CAS  PubMed  Google Scholar 

  32. Blijlevens NM, Donnelly JP, de Pauw BE. Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy. Clin Microbiol Infect. 2001;7 Suppl 4:47–52.

    PubMed  Google Scholar 

  33. Boktour M, Hanna H, Ansari S, et al. Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer. 2006;106:1967–73.

    PubMed  Google Scholar 

  34. Bonadio M, Morelli G, Mori S, et al. Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with infectious complications. Biomed Pharmacother. 2005;59:511–6.

    CAS  PubMed  Google Scholar 

  35. Brook I. The role of anaerobic bacteria in bacteremia. Anaerobe. 2010;16:183–9.

    CAS  PubMed  Google Scholar 

  36. Bruckner L, Gigliotti F. Alpha-hemolytic streptococcal infections among immunocompromised hosts: increasing incidence, severity and antibiotic resistance. Pediatr Infect Dis J. 2002;21:343–5.

    PubMed  Google Scholar 

  37. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–87.

    CAS  PubMed  Google Scholar 

  38. Busca A, Cavecchia I, Locatelli F, et al. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis. Transpl Infect Dis. 2012;14:40–8.

    CAS  PubMed  Google Scholar 

  39. Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J Infect. 2010;60:331–7.

    PubMed  Google Scholar 

  40. Camps SM, van der Linden JW, Li Y, et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother. 2012;56:10–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  41. Cappellano P, Viscoli C, Bruzzi P, et al. Epidemiology and risk factors for bloodstream infections after allogeneic hematopoietic stem cell transplantation. New Microbiol. 2007;30:89–99.

    PubMed  Google Scholar 

  42. Caselli D, Cesaro S, Ziino O, et al. Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica. 2010;95:1612–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  43. Castagnola E, Caviglia I, Pistorio A, et al. Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer. 2005;41:1439–45.

    PubMed  Google Scholar 

  44. Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 2008;61:721–8.

    CAS  PubMed  Google Scholar 

  45. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica. 2006;91:986–9.

    PubMed  Google Scholar 

  46. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis. 2006;25:215–29.

    CAS  PubMed  Google Scholar 

  47. Chee L, Brown M, Sasadeusz J, MacGregor L, Grigg AP. Gram-negative organisms predominate in Hickman line-related infections in non-neutropenic patients with hematological malignancies. J Infect. 2008;56:227–33.

    CAS  PubMed  Google Scholar 

  48. Chen CY, Tang JL, Hsueh PR, et al. Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. J Formos Med Assoc. 2004;103:526–32.

    CAS  PubMed  Google Scholar 

  49. Chen CY, Tsay W, Tang JL, et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect. 2010;138:1044–51.

    PubMed  Google Scholar 

  50. Chong Y, Yakushiji H, Ito Y, Kamimura T. Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies. Int J Infect Dis. 2010;14 Suppl 3:e171–5.

    PubMed  Google Scholar 

  51. Chopra T, Chandrasekar P, Salimnia H, et al. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant. 2011;25:E82–7.

    PubMed  Google Scholar 

  52. Chowdhary A, Meis JF, Guarro J, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect. 2014;20 Suppl 3:47–75.

    CAS  PubMed  Google Scholar 

  53. Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001;33:947–53.

    CAS  PubMed  Google Scholar 

  54. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37:382–9.

    CAS  PubMed  Google Scholar 

  55. Cordonnier C, Buzyn A, Leverger G, et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis. 2003;36:149–58.

    PubMed  Google Scholar 

  56. Cordonnier C, Herbrecht R, Buzyn A, et al. Risk factors for Gram-negative bacterial infections in febrile neutropenia. Haematologica. 2005;90:1102–9.

    PubMed  Google Scholar 

  57. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20 Suppl 3:5–26.

    CAS  PubMed  Google Scholar 

  58. Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis. 2006;43:577–84.

    CAS  PubMed  Google Scholar 

  59. Craig M, Cumpston AD, Hobbs GR, et al. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. Bone Marrow Transplant. 2007;39:477–82.

    CAS  PubMed  Google Scholar 

  60. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23:616–87.

    CAS  PubMed Central  PubMed  Google Scholar 

  61. Debbache K, Varon E, Hicheri Y, et al. The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines? Clin Microbiol Infect. 2009;15:865–8.

    CAS  PubMed  Google Scholar 

  62. Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011;52:1123–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  63. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis. 2007;44:1543–8.

    CAS  PubMed  Google Scholar 

  64. Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (‘the MIC Creep’): implications for therapy. F1000 Med Rep. 2012;4:4.

    PubMed Central  PubMed  Google Scholar 

  65. Donnelly JP, Dompeling EC, Meis JF, de Pauw BE. Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: cytostatics are a more important risk factor than antibacterial prophylaxis. Clin Infect Dis. 1995;20:469–70.

    CAS  PubMed  Google Scholar 

  66. Durante-Mangoni E, Zarrilli R. Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. Future Microbiol. 2011;6:407–22.

    PubMed  Google Scholar 

  67. Dutronc H, Billhot M, Dupon M, et al. Management of 315 neutropenic febrile episodes in a cancer center. Med Mal Infect. 2009;39:388–93.

    CAS  PubMed  Google Scholar 

  68. ECDC. Antimicrobial resistance surveillance in Europe 2010. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, ECDC. 2011. http://www.ecdc.europa.eu/en/publications/Publications/1111_SUR_AMR_data.pdf. Accessed 19 Mar 2012.

  69. El-Mahallawy H, Sidhom I, El-Din NH, Zamzam M, El-Lamie MM. Clinical and microbiologic determinants of serious bloodstream infections in Egyptian pediatric cancer patients: a one-year study. Int J Infect Dis. 2005;9:43–51.

    CAS  PubMed  Google Scholar 

  70. Elishoov H, Or R, Strauss N, Engelhard D. Nosocomial colonization, septicemia, and Hickman/Broviac catheter-related infections in bone marrow transplant recipients. A 5-year prospective study. Medicine (Baltimore). 1998;77:83–101.

    CAS  Google Scholar 

  71. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992;14:1201–7.

    CAS  PubMed  Google Scholar 

  72. Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002;117:444–50.

    PubMed  Google Scholar 

  73. Falcone M, Micozzi A, Pompeo ME, et al. Methicillin-resistant staphylococcal bacteremia in patients with hematologic malignancies: clinical and microbiological retrospective comparative analysis of S. haemolyticus, S. epidermidis and S. aureus. J Chemother. 2004;16:540–8.

    CAS  PubMed  Google Scholar 

  74. Faraci M, Lanino E, Morreale G, et al. Bacteremias and invasive fungal diseases in children receiving etanercept for steroid-resistant acute GVHD. Bone Marrow Transplant. 2011;46:159–60.

    CAS  PubMed  Google Scholar 

  75. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979–95.

    PubMed  Google Scholar 

  76. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.

    PubMed Central  PubMed  Google Scholar 

  77. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother. 2007;59:5–22.

    CAS  PubMed  Google Scholar 

  78. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis. 2010;23:332–9.

    PubMed  Google Scholar 

  79. Ghosh I, Raina V, Kumar L, et al. Profile of infections and outcome in high-risk febrile neutropenia: experience from a tertiary care cancer center in India. Med Oncol. 2011;29:1354–60.

    PubMed  Google Scholar 

  80. Girmenia C, Martino P, De Bernardis F, et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis. 1996;23:506–14.

    CAS  PubMed  Google Scholar 

  81. Girmenia C, Pagano L, Martino B, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol. 2005;43:1818–28.

    PubMed Central  PubMed  Google Scholar 

  82. Girmenia C, Pizzarelli G, D’Antonio D, Cristini F, Martino P. In vitro susceptibility testing of Geotrichum capitatum: comparison of the E-test, disk diffusion, and Sensititre colorimetric methods with the NCCLS M27-A2 broth microdilution reference method. Antimicrob Agents Chemother. 2003;47:3985–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  83. Gomez L, Garau J, Estrada C, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer. 2003;97:419–24.

    CAS  PubMed  Google Scholar 

  84. Gonzalez-Barca E, Carratala J, Mykietiuk A, Fernandez-Sevilla A, Gudiol F. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur J Clin Microbiol Infect Dis. 2001;20:117–9.

    CAS  PubMed  Google Scholar 

  85. Greenberg D, Moser A, Yagupsky P, et al. Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols. Int J Antimicrob Agents. 2005;25:469–73.

    CAS  PubMed  Google Scholar 

  86. Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother. 2011;66:657–63.

    CAS  PubMed  Google Scholar 

  87. Guthrie KA, Yong M, Frieze D, Corey L, Fredricks DN. The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45:675–81.

    CAS  PubMed Central  PubMed  Google Scholar 

  88. Guven GS, Uzun O, Cakir B, Akova M, Unal S. Infectious complications in patients with hematological malignancies consulted by the infectious diseases team: a retrospective cohort study (1997–2001). Support Care Cancer. 2006;14:52–5.

    PubMed  Google Scholar 

  89. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112:2493–9.

    PubMed  Google Scholar 

  90. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect. 2002;50:56–65.

    CAS  PubMed  Google Scholar 

  91. Hoppe JE, Herter M, Aleksic S, Klingebiel T, Niethammer D. Catheter-related Rahnella aquatilis bacteremia in a pediatric bone marrow transplant recipient. J Clin Microbiol. 1993;31:1911–2.

    CAS  PubMed Central  PubMed  Google Scholar 

  92. Horasan ES, Ersoz G, Tombak A, Tiftik N, Kaya A. Bloodstream infections and mortality-related factors in febrile neutropenic cancer patients. Med Sci Monit. 2011;17:CR304–9.

    PubMed Central  PubMed  Google Scholar 

  93. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695–703.

    CAS  PubMed  Google Scholar 

  94. Hsueh PR, Teng LJ, Ho SW, Luh KT. Catheter-related sepsis due to Rhodotorula glutinis. J Clin Microbiol. 2003;41:857–9.

    PubMed Central  PubMed  Google Scholar 

  95. Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40:89–99.

    PubMed  Google Scholar 

  96. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39:743–6.

    PubMed  Google Scholar 

  97. Imran H, Tleyjeh IM, Arndt CA, et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis. 2008;27:53–63.

    CAS  PubMed  Google Scholar 

  98. Jin J, Lee YM, Ding Y, et al. Prospective audit of febrile neutropenia management at a tertiary university hospital in Singapore. Ann Acad Med Singapore. 2010;39:453–9.

    PubMed  Google Scholar 

  99. Johnson AP. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother. 2011;66 Suppl 4:iv43–8.

    CAS  PubMed  Google Scholar 

  100. Johnson LE, D’Agata EM, Paterson DL, et al. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis. 2009;11:227–34.

    CAS  PubMed  Google Scholar 

  101. Jones RN. Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol Infect. 2008;14 Suppl 2:3–9.

    CAS  PubMed  Google Scholar 

  102. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006;42 Suppl 1:S13–24.

    CAS  PubMed  Google Scholar 

  103. Kamboj M, Chung D, Seo SK, et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant. 2010;16:1576–81.

    PubMed Central  PubMed  Google Scholar 

  104. Kanafani ZA, Dakdouki GK, El-Chammas KI, et al. Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade. Int J Infect Dis. 2007;11:450–3.

    PubMed  Google Scholar 

  105. Kara O, Zarakolu P, Ascioglu S, Buyukasik Y, Akova M. Changing epidemiology with emerging resistance of bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abstract no. K-959. American Society for Microbiology: Boston.; 2010.

    Google Scholar 

  106. Kawalec M, Kedzierska J, Gajda A, et al. Hospital outbreak of vancomycin-resistant enterococci caused by a single clone of Enterococcus raffinosus and several clones of Enterococcus faecium. Clin Microbiol Infect. 2007;13:893–901.

    CAS  PubMed  Google Scholar 

  107. Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1999;341:312–8.

    CAS  PubMed  Google Scholar 

  108. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24:111–8.

    CAS  PubMed  Google Scholar 

  109. Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trail comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy-EORTC infectious diseases group trial XV. J Clin Oncol. 2013;31:1149–56.

    CAS  PubMed  Google Scholar 

  110. Kern WV, Steib-Bauert M, de With K, et al. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999–2002. J Antimicrob Chemother. 2005;55:57–60.

    CAS  PubMed  Google Scholar 

  111. Kirby JT, Fritsche TR, Jones RN. Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America). Diagn Microbiol Infect Dis. 2006;56:75–82.

    CAS  PubMed  Google Scholar 

  112. Kirdar S, Sener AG, Arslan U, Yurtsever SG. Molecular epidemiology of vancomycin-resistant Enterococcus faecium strains isolated from haematological malignancy patients in a research hospital in Turkey. J Med Microbiol. 2010;59:660–4.

    CAS  PubMed  Google Scholar 

  113. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30 Suppl 1:S51–9.

    CAS  PubMed  Google Scholar 

  114. Klastersky J, Zinner SH, Calandra T, et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol. 1988;24 Suppl 1:S35–45.

    PubMed  Google Scholar 

  115. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–100.

    PubMed  Google Scholar 

  116. Kraft S, Mackler E, Schlickman P, Welch K, DePestel DD. Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Support Care Cancer. 2011;19:1969–74.

    PubMed  Google Scholar 

  117. Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood. 2000;95:3683–6.

    CAS  PubMed  Google Scholar 

  118. Kullberg BJ, Verweij PE, Akova M, et al. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect. 2011;17 Suppl 5:1–12.

    PubMed  Google Scholar 

  119. Kumashi P, Girgawy E, Tarrand JJ, et al. Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998–2002). Medicine (Baltimore). 2005;84:303–12.

    Google Scholar 

  120. Lamaris GA, Chamilos G, Lewis RE, et al. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989–2006. Clin Infect Dis. 2006;43:1580–4.

    PubMed  Google Scholar 

  121. Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009;52:197–205.

    PubMed  Google Scholar 

  122. Lass-Florl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol. 2005;131:201–7.

    PubMed  Google Scholar 

  123. Lautenbach E, Metlay JP, Weiner MG, et al. Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol. 2009;30:18–24.

    PubMed Central  PubMed  Google Scholar 

  124. Lin MY, Weinstein RA, Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother. 2008;52:3188–94.

    CAS  PubMed Central  PubMed  Google Scholar 

  125. Lopez-Dupla M, Martinez JA, Vidal F, et al. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. Am J Infect Control. 2009;37:753–8.

    PubMed  Google Scholar 

  126. Lortholary O, Dannaoui E, Raoux D, et al. In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother. 2007;51:3378–80.

    CAS  PubMed Central  PubMed  Google Scholar 

  127. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005;41:435–40.

    CAS  PubMed  Google Scholar 

  128. Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155:318–27.

    CAS  PubMed Central  PubMed  Google Scholar 

  129. Marr KA. Fungal infections in hematopoietic stem cell transplant recipients. Med Mycol. 2008;46:293–302.

    PubMed  Google Scholar 

  130. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–66.

    CAS  PubMed  Google Scholar 

  131. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–17.

    PubMed  Google Scholar 

  132. Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol. 2002;116:475–82.

    PubMed  Google Scholar 

  133. Matar MJ, Safdar A, Rolston KV. Relationship of colonization with vancomycin-resistant enterococci and risk of systemic infection in patients with cancer. Clin Infect Dis. 2006;42:1506–7.

    PubMed  Google Scholar 

  134. Meletiadis J, Meis JF, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother. 2002;46:62–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  135. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51:1897–904.

    CAS  PubMed Central  PubMed  Google Scholar 

  136. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011;11:142–51.

    PubMed  Google Scholar 

  137. Mihu CN, Schaub J, Kesh S, et al. Risk factors for late Staphylococcus aureus bacteremia after allogeneic hematopoietic stem cell transplantation: a single-institution, nested case-controlled study. Biol Blood Marrow Transplant. 2008;14:1429–33.

    PubMed  Google Scholar 

  138. Mikulska M, Del Bono V, Prinapori R, et al. Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2010;12:505–12.

    CAS  PubMed  Google Scholar 

  139. Mikulska M, Del Bono V, Raiola AM, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant. 2009;15:47–53.

    CAS  PubMed  Google Scholar 

  140. Mikulska M, Viscoli C, Orasch C, et al. ECIL 4: bacterial resistance in haematology. J Infect. 2014;68(4):321–31.

    PubMed  Google Scholar 

  141. Moudgal V, Sobel JD. Clostridium difficile colitis: a review. Hosp Pract (Minneap). 2012;40:139–48.

    Google Scholar 

  142. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48:265–73.

    CAS  PubMed  Google Scholar 

  143. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38:1237–42.

    PubMed  Google Scholar 

  144. Nunes AP, Teixeira LM, Iorio NL, et al. Heterogeneous resistance to vancomycin in Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus warneri clinical strains: characterisation of glycopeptide susceptibility profiles and cell wall thickening. Int J Antimicrob Agents. 2006;27:307–15.

    CAS  PubMed  Google Scholar 

  145. Oh HS, Kim EC, Oh MD, Choe KW. Outbreak of vancomycin resistant enterococcus in a hematology/oncology unit in a Korean University Hospital, and risk factors related to patients, staff, hospital care and facilities. Scand J Infect Dis. 2004;36:790–4.

    PubMed  Google Scholar 

  146. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis. 2005;40:770–1.

    PubMed  Google Scholar 

  147. Ortega M, Marco F, Soriano A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother. 2009;63:568–74.

    CAS  PubMed  Google Scholar 

  148. Ortega M, Rovira M, Almela M, et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol. 2005;84:40–6.

    PubMed  Google Scholar 

  149. Paez JI, Tengan FM, Barone AA, Levin AS, Costa SF. Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis. 2008;27:901–6.

    PubMed  Google Scholar 

  150. Pagano L, Akova M, Dimopoulos G, et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66 Suppl 1:i5–14.

    CAS  PubMed  Google Scholar 

  151. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068–75.

    PubMed  Google Scholar 

  152. Pagano L, Caira M, Nosari A, et al. Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e-Chart Registry. Arch Intern Med. 2011;171:1502–3.

    PubMed  Google Scholar 

  153. Pagano L, Caira M, Picardi M, et al. Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality—SEIFEM-C report. Clin Infect Dis. 2007;44:1524–5.

    PubMed  Google Scholar 

  154. Pagano L, Caira M, Rossi G, et al. A prospective survey of febrile events in hematological malignancies. Ann Hematol. 2012;91:767–74.

    CAS  PubMed  Google Scholar 

  155. Pagano L, Tacconelli E, Tumbarello M, et al. Teicoplanin-resistant coagulase-negative staphylococcal bacteraemia in patients with haematological malignancies: a problem of increasing importance. J Antimicrob Chemother. 1997;40:738–40.

    CAS  PubMed  Google Scholar 

  156. Pakyz AL, Farr BM. Rates of Stenotrophomonas maltophilia colonization and infection in relation to antibiotic cycling protocols. Epidemiol Infect. 2009;137:1679–83.

    CAS  PubMed  Google Scholar 

  157. Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006. Emerg Infect Dis. 2011;17:1855–64.

    PubMed Central  PubMed  Google Scholar 

  158. Paul M, Gafter-Gvili A, Leibovici L, et al. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988–2004. Isr Med Assoc J. 2007;9:424–9.

    PubMed  Google Scholar 

  159. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–60.

    CAS  PubMed  Google Scholar 

  160. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122–31.

    CAS  PubMed  Google Scholar 

  161. Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54 Suppl 1:S23–34.

    PubMed  Google Scholar 

  162. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010;36:1–53.

    PubMed  Google Scholar 

  163. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004;42:4419–31.

    CAS  PubMed Central  PubMed  Google Scholar 

  164. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009). Int J Antimicrob Agents. 2011;38:65–9.

    CAS  PubMed  Google Scholar 

  165. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42:1398–403.

    CAS  PubMed  Google Scholar 

  166. Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer. 2010;116:967–73.

    PubMed  Google Scholar 

  167. Richard P, Amador Del Valle G, Moreau P, et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet. 1995;345:1607–9.

    CAS  PubMed  Google Scholar 

  168. Rogers KL, Fey PD, Rupp ME. Coagulase-negative staphylococcal infections. Infect Dis Clin North Am. 2009;23:73–98.

    PubMed  Google Scholar 

  169. Rolston KV, Jiang Y, Matar M. VRE fecal colonization/infection in cancer patients. Bone Marrow Transplant. 2007;39:567–8.

    CAS  PubMed  Google Scholar 

  170. Rolston KV, Yadegarynia D, Kontoyiannis DP, Raad II, Ho DH. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients. Int J Infect Dis. 2006;10:223–30.

    CAS  PubMed  Google Scholar 

  171. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45:1602–9.

    PubMed  Google Scholar 

  172. Sahin GO, Akova M. Treatment of invasive infections due to rare or emerging yeasts and moulds. Expert Opin Pharmacother. 2006;7:1181–90.

    CAS  PubMed  Google Scholar 

  173. Saito T, Yoshioka S, Iinuma Y, et al. Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit. Eur J Clin Microbiol Infect Dis. 2008;27:209–16.

    CAS  PubMed  Google Scholar 

  174. Sanchez MB, Hernandez A, Martinez JL. Stenotrophomonas maltophilia drug resistance. Future Microbiol. 2009;4:655–60.

    CAS  PubMed  Google Scholar 

  175. Sanchez MB, Hernandez A, Rodriguez-Martinez JM, Martinez-Martinez L, Martinez JL. Predictive analysis of transmissible quinolone resistance indicates Stenotrophomonas maltophilia as a potential source of a novel family of Qnr determinants. BMC Microbiol. 2008;8:148.

    PubMed Central  PubMed  Google Scholar 

  176. Sanz Alonso MA, Jarque Ramos I, Salavert Lletí M, Pemán J. Epidemiology of invasive fungal infections due to Aspergillus spp. and Zygomycetes. Clin Microbiol Infect. 2006;12:2–6.

    Google Scholar 

  177. Shaw BE, Boswell T, Byrne JL, Yates C, Russell NH. Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant. 2007;39:623–9.

    CAS  PubMed  Google Scholar 

  178. Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Am J Infect Control. 2007;35:S65–164.

    PubMed  Google Scholar 

  179. Sigurdardottir K, Digranes A, Harthug S, et al. A multi-centre prospective study of febrile neutropenia in Norway: microbiological findings and antimicrobial susceptibility. Scand J Infect Dis. 2005;37:455–64.

    PubMed  Google Scholar 

  180. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39:584–7.

    PubMed  Google Scholar 

  181. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859–67.

    CAS  PubMed  Google Scholar 

  182. Snelders E, Camps SM, Karawajczyk A, et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One. 2012;7:e31801.

    CAS  PubMed Central  PubMed  Google Scholar 

  183. Snelders E, Huis In ‘t Veld RA, Rijs AJ, et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 2009;75:4053–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  184. Snelders E, Melchers WJ, Verweij PE. Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol. 2011;6:335–47.

    CAS  PubMed  Google Scholar 

  185. Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e219.

    PubMed Central  PubMed  Google Scholar 

  186. Timmers GJ, van der Zwet WC, Simoons-Smit IM, et al. Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic. Br J Haematol. 2002;116:826–33.

    PubMed  Google Scholar 

  187. Tortorano AM, Kibbler C, Peman J, et al. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents. 2006;27:359–66.

    CAS  PubMed  Google Scholar 

  188. Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20 Suppl 3:27–46.

    CAS  PubMed  Google Scholar 

  189. Trecarichi EM, Tumbarello M, Caira M, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica. 2011;96:e1–3. author reply e4.

    PubMed Central  PubMed  Google Scholar 

  190. Trecarichi EM, Tumbarello M, Spanu T, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58:299–307.

    PubMed  Google Scholar 

  191. Tumbarello M, Spanu T, Di Bidino R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54:4085–91.

    CAS  PubMed Central  PubMed  Google Scholar 

  192. Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother. 2011;55:3485–90.

    CAS  PubMed Central  PubMed  Google Scholar 

  193. Tuon FF, Costa SF. Rhodotorula infection. A systematic review of 128 cases from literature. Rev Iberoam Micol. 2008;25:135–40.

    PubMed  Google Scholar 

  194. Turkoglu M, Mirza E, Tunccan OG, et al. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011;26:460–7.

    PubMed  Google Scholar 

  195. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44:531–40.

    PubMed  Google Scholar 

  196. van der Linden JW, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med Mycol. 2011;49 Suppl 1:S82–9.

    Google Scholar 

  197. Vardakas KZ, Polyzos KA, Patouni K, et al. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents. 2012;40:1–8.

    CAS  PubMed  Google Scholar 

  198. Velasco E, Byington R, Martins CA, et al. Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections. Eur J Clin Microbiol Infect Dis. 2006;25:1–7.

    CAS  PubMed  Google Scholar 

  199. Venditti M, Falcone M, Micozzi A, et al. Staphylococcus aureus bacteremia in patients with hematologic malignancies: a retrospective case-control study. Haematologica. 2003;88:923–30.

    PubMed  Google Scholar 

  200. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356:1481–3.

    CAS  PubMed  Google Scholar 

  201. Vigil KJ, Adachi JA, Aboufaycal H, et al. Multidrug-resistant Escherichia coli bacteremia in cancer patients. Am J Infect Control. 2009;37:741–5.

    PubMed  Google Scholar 

  202. Viscoli C. Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer. 2002;38 Suppl 4:S82–7.

    PubMed  Google Scholar 

  203. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28:1071–9.

    CAS  PubMed  Google Scholar 

  204. von Baum H, Sigge A, Bommer M, et al. Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother. 2006;58:891–4.

    Google Scholar 

  205. Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004;10 Suppl 1:48–66.

    PubMed  Google Scholar 

  206. Walsh TJ, Peter J, McGough DA, et al. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother. 1995;39:1361–4.

    CAS  PubMed Central  PubMed  Google Scholar 

  207. Weinstock DM, Conlon M, Iovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007;13:615–21.

    PubMed  Google Scholar 

  208. Willems L, Porcher R, Lafaurie M, et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 2012;18:1295–301.

    PubMed  Google Scholar 

  209. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  210. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103–10.

    PubMed  Google Scholar 

  211. Worth LJ, Slavin MA. Bloodstream infections in haematology: risks and new challenges for prevention. Blood Rev. 2009;23:113–22.

    PubMed  Google Scholar 

  212. Yoo JH, Lee DG, Choi SM, et al. Vancomycin-resistant enterococcal bacteremia in a hematology unit: molecular epidemiology and analysis of clinical course. J Korean Med Sci. 2005;20:169–76.

    CAS  PubMed Central  PubMed  Google Scholar 

  213. Yoshida M, Akiyama N, Fujita H, et al. Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int J Hematol. 2011;93:66–73.

    PubMed  Google Scholar 

  214. Youssef S, Rodriguez G, Rolston KV, et al. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989–2005. Medicine (Baltimore). 2007;86:69–77.

    Google Scholar 

  215. Zahar JR, Farhat H, Chachaty E, et al. Incidence and clinical significance of anaerobic bacteraemia in cancer patients: a 6-year retrospective study. Clin Microbiol Infect. 2005;11:724–9.

    PubMed  Google Scholar 

  216. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991–2000. Clin Infect Dis. 2003;37:1643–8.

    CAS  PubMed  Google Scholar 

  217. Zirakzadeh A, Gastineau DA, Mandrekar JN, et al. Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2008;41:385–92.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey

    Murat Akova

Authors
  1. Murat Akova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Murat Akova .

Editor information

Editors and Affiliations

  1. Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany

    Georg Maschmeyer

  2. Department of Infectious Diseases, Infection Control and Employee Health, M.D. Anderson Cancer Center University of Texas, Houston, Texas, USA

    Kenneth V.I. Rolston

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Akova, M. (2015). Microbiological Background. In: Maschmeyer, G., Rolston, K. (eds) Infections in Hematology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44000-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-44000-1_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43999-9

  • Online ISBN: 978-3-662-44000-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation